Natco Pharma Q1 FY27 Results

Revenue: Rs 794.4 crore
PAT: Rs 206.5 crore

Reader Takeaway: Revenue dip due to product cycles, offset by base business growth and strategic investments.

What just happened

Natco Pharma reported a consolidated revenue of Rs 794.4 crore for the first quarter of FY27. This marks a significant decrease from Rs 1,390.6 crore in the same quarter last year. The company's Profit After Tax (PAT) stood at Rs 206.5 crore.

Why this matters

The revenue decline, mainly due to lower sales of Lenalidomide, highlights the impact of product tender cycles on the company's top line. However, a 30.9% EBITDA margin and robust PAT indicate strong operational efficiency and profitability from other business segments.

The backstory

Natco Pharma has been strategically increasing its stake in associate firm Adcock Ingram, reaching 49% in July 2026. The company also deployed approximately Rs 3,000 crore in the last year, largely for this acquisition, and currently holds about Rs 1,400 crore in net cash.

What changes now

A potential fundraising plan of up to Rs 2,000 crore has been announced to fund future Mergers & Acquisitions (M&A), capital expenditure, and debt repayment. Management has maintained its full-year PAT guidance at Rs 750 crore and gross sales target of Rs 3,300-3,400 crore.

The demerger of the Crop Health business has been delayed by 2-3 months, now expected around March 2027. Brazil operations showed strong 180% growth, contributing Rs 178 crore in revenue.

Risks to watch

Revenue can be volatile due to the nature of product tenders. The Semaglutide market faces intense competition. Any future fundraising might lead to equity dilution. The Crop Health demerger timeline could face further delays.

Peer comparison

While specific peer financial data for Q1 FY27 is not provided in the filing, Natco Pharma operates in the competitive pharmaceutical sector. Its performance in specific product segments like Lenalidomide and emerging markets like Brazil should be viewed against industry trends and competitor performance.

Context metrics (time-bound)

• Q1 FY27 Revenue: Rs 794.4 crore
• Q1 FY26 Revenue: Rs 1,390.6 crore
• Q1 FY27 PAT: Rs 206.5 crore
• EBITDA Margin: 30.9%
• Brazil Revenue: Rs 178 crore (180% growth)
• Canada Sales: Rs 56 crore
• Crop Health Revenue: Rs 40 crore
• Net Cash: Approx. Rs 1,400 crore
• Adcock Ingram stake: Increased to 49%

What to track next

Investors will be watching the progress of the Rs 2,000 crore fundraising, the finalization of M&A activities, and the revised timeline for the Crop Health demerger. Performance in the base business and international markets like Brazil will also be key indicators.